View all available purchase options and get full access to this article. Nie X, Liu X, Wang C, Wu Z, Sun Z, Su J, Yan R, Peng Y, Yang Y, Wang C, et al. Assessment of evidence on reported non-genetic ...

a private biotech company focused on developing transformative therapies for chronic eye diseases, announced that the U.S. Food and Drug Administration (FDA), has approved ENCELTO™(revakinagene ...

Revakinagene taroretcel-lwey is the first FDA-approved treatment for macular telangiectasia type 2, a progressive neurodegenerative retinal disease. The therapy uses an encapsulated cell-based ...

Encelto is the first FDA-approved treatment for macular telangiectasia type 2. The cell therapy slows the loss of macular photoreceptors through continuous delivery of ciliary neurotrophic factor.

Encelto, the first FDA-approved treatment for MacTel, is implanted intravitreally during a surgery performed by a qualified ophthalmologist. The Food and Drug Administration (FDA) has approved ...

The name comes from a combination from Greek words meaning “water” and “head.” “Congenital” means a person is born with it. The liquid that builds up isn’t water. It’s ...

Congenital heart disease (CHD) is a variety of structural and functional abnormalities in the heart that are present at birth. These conditions can affect the heart's chambers, valves, or blood ...